Ricard Cervera
Autoimmune Diseases Service Rheumatologist and Head of serviceResearch group
- Systemic autoimmune diseases Group leader (R4)
About me
Ricard Cervera, MD, PhD, FRCP is Senior Consultant and Head at the Department of Autoimmune Diseases, Hospital Clínic de Barcelona, Director of the Research Group on Systemic Autoimmune Diseases at the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) of Barcelona, Professor and Director of the UB-GSK Chair on Autoimmune Diseases, Coordinator of the Masters’ on Autoimmune Diseases and Academic Vice-Dean at the Faculty of Medicine and Health Sciences of the University of Barcelona (UB).
Featured publications
-
Persistence of antiphospholipid antibodies over time and its association with recurrence of clinical manifestations: A longitudinal study from a single centre
Authors:Reference: Autoimmunity Reviews 2022. -
Accrual of organ damage in Behçet's syndrome: trajectory, associated factors, and impact on patients' quality of life over a 2-year prospective follow-up study
Authors:Reference: Arthritis Research & Therapy 2022. -
Kidney biopsy in lupus nephritis after achieving clinical renal remission: paving the way for renal outcome assessment
Authors:Reference: Clinical Kidney Journal 2022. -
Why lupus patients discontinue antimalarials in real life: A 50 years-experience from a reference centre
Authors:Reference: Lupus 2022. -
Persistent Antiphospholipid Antibodies Are Not Associated With Worse Clinical Outcomes in a Prospective Cohort of Hospitalised Patients With SARS-CoV-2 Infection
Authors:Reference: Frontiers In Immunology 2022. -
Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and Repository
Authors:Reference: Arthritis Care & Research 2022. -
Cost-effectiveness analysis of treatments for the first episode of catastrophic antiphospholipid syndrome: A study based on the catastrophic antiphospholipid syndrome registry
Authors:Reference: Lupus 2022. -
The presence of non-criteria manifestations negatively affects the prognosis of seronegative antiphospholipid syndrome patients: a multicenter study
Authors:Reference: Arthritis Research & Therapy 2022.
Featured Projects
-
Taxonomy, Treatment, Targets and Remission (3TR): Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions
Principal investigator: Juan de Dios Canete Crespillo, Maria Azucena Salas Martinez, Luis F Quintana Porras, Ricard Cervera Segura, Yolanda Blanco MorgadoFunder: European CommissionCode: CE_IMI2-2018-14Duration: 01/09/2019 - 31/08/2026 -
Redes de Investigación Cooperativa Orientadas a Resultados en Salud 2021: Enfermedades inflamatorias
Principal investigator: Ricard Cervera SeguraFunder: Instituto de Salud Carlos IIICode: FIS_RICORS21Duration: 01/01/2022 - 31/12/2024 -
Estudio multimodal de imagen para el diagnóstico y pronóstico de los pacientes con lupus eritematoso sistémico
Principal investigator: Laura Pelegrin Colas, Gerard Espinosa GarrigaFunder: Instituto de Salud Carlos IIICode: PI20/01104Duration: 01/01/2021 - 31/12/2023 -
Papel de las citocinas implicadas en el desarrollo y activación de los linfocitos B y la proteína Dicckopf-3 como marcadores urinarios de fibrosis tubulointersticial en los pacientes con nefritis lúpica
Principal investigator: Luis F Quintana Porras, Marc Xipell FontFunder: Premi Fi de Residència de l´Hospital Clínic de BarcelonaDuration: 01/01/2021 - 01/01/2023 -
Caracterización fenotípica y funcional de linfocitos, monocitos y macrófagos mediante citometría de flujo del sedimento urinario en pacientes con nefritis lúpica para la predicción de enferemdad renal crónica
Principal investigator: Luis F Quintana PorrasFunder: Fundación Sociedad Española de Nefrología (SENEFRO)Duration: 23/12/2020 - 22/12/2023